Browse by Audience
Skip to content
Papers of the Week
An overview of benvitimod for the treatment of psoriasis: a narrative review.
Authors
Abstract
The most frequently prescribed first-line treatment for limited (mild-to-moderate) psoriasis is topical corticosteroids, which are associated with a number of adverse effects with long term use. Benvitimod is an aryl hydrocarbon receptor immunomodulator that is both efficacious and tolerable for use in patients with mild to severe psoriasis with a body surface area (BSA) range of 1-20%.